ES2123064T3 - Uso de melatonina en pequeñas dosis orales como somnifero. - Google Patents

Uso de melatonina en pequeñas dosis orales como somnifero.

Info

Publication number
ES2123064T3
ES2123064T3 ES93923164T ES93923164T ES2123064T3 ES 2123064 T3 ES2123064 T3 ES 2123064T3 ES 93923164 T ES93923164 T ES 93923164T ES 93923164 T ES93923164 T ES 93923164T ES 2123064 T3 ES2123064 T3 ES 2123064T3
Authority
ES
Spain
Prior art keywords
melatonin
somnifero
oral dose
small oral
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923164T
Other languages
English (en)
Inventor
Richard J Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of ES2123064T3 publication Critical patent/ES2123064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Indole Compounds (AREA)

Abstract

METODOS DE INDUCCION DE LA SOMNOLENCIA Y DEL SUEÑO POR ADMINISTRACION A UN INDIVIDUO DE UNA UNICA DOSIS DE MELATONINA SUFICIENTE PARA INDUCIR LA SOMNOLENCIA Y EL SUEÑO EN EL INDIVIDUO.
ES93923164T 1992-10-01 1993-09-29 Uso de melatonina en pequeñas dosis orales como somnifero. Expired - Lifetime ES2123064T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95530492A 1992-10-01 1992-10-01
US08/093,317 US5449683A (en) 1992-10-01 1993-07-16 Methods of inducing sleep using melatonin

Publications (1)

Publication Number Publication Date
ES2123064T3 true ES2123064T3 (es) 1999-01-01

Family

ID=26787395

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923164T Expired - Lifetime ES2123064T3 (es) 1992-10-01 1993-09-29 Uso de melatonina en pequeñas dosis orales como somnifero.

Country Status (9)

Country Link
US (2) US5449683A (es)
EP (1) EP0663825B1 (es)
JP (1) JP3133760B2 (es)
AT (1) ATE169816T1 (es)
CA (1) CA2146151C (es)
DE (1) DE69320485T2 (es)
DK (1) DK0663825T3 (es)
ES (1) ES2123064T3 (es)
WO (1) WO1994007487A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5530012A (en) * 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
AU4569496A (en) * 1995-02-24 1996-09-05 Bristol-Myers Squibb Company Tetralinyl- and indanyl-ethylamides
US5661186A (en) * 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides
US5736578A (en) * 1995-06-06 1998-04-07 Bristol-Myers Squibb Company Ethylamido fluorenes and improved method of making same
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
EP0837850B1 (en) * 1995-06-27 2004-09-01 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
CA2186412A1 (en) 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
DE19713141A1 (de) * 1996-03-29 1997-10-30 Labtec Gmbh Transdermales System mit Melatonin
US5808151A (en) * 1996-04-17 1998-09-15 Bristol-Myers Squibb Company Biphenylamido derivatives as melatonergic agents
ZA9711051B (en) * 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
WO1998038991A1 (en) * 1997-03-05 1998-09-11 Bristol-Myers Squibb Company Polycyclic ethyl alkylamide melatonergic agents
NZ501321A (en) * 1997-03-26 2001-04-27 Franciscus W Nasal Melatonin composition
EP0867181A1 (en) * 1997-03-26 1998-09-30 Franciscus Wilhelmus Henricus Maria Merkus Nasal melatonin composition
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
US6028112A (en) * 1997-05-23 2000-02-22 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
WO1999048859A1 (en) * 1998-03-20 1999-09-30 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
EP1189900B1 (en) 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
EP1545511B1 (en) * 2002-09-26 2007-05-09 Pooger Properties Limited Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
US6703412B1 (en) 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
TW200533299A (en) * 2004-03-31 2005-10-16 Calpis Co Ltd Functional food for improving endogenous rhythm of melatonin secretion, and functional food for improving circadian rhythm
WO2005097101A1 (ja) * 2004-04-06 2005-10-20 Taiyokagaku Co., Ltd. 睡眠改善用組成物
US7364583B2 (en) 2004-04-23 2008-04-29 Physician Engineered Products Inc. Head mounted photoeffective device
US7546165B2 (en) * 2005-12-19 2009-06-09 Cardiac Pacemakers, Inc. Interconnections of implantable lead conductors and electrodes and reinforcement therefor
EP1991241A4 (en) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
US20080171085A1 (en) * 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US10369310B2 (en) * 2014-03-05 2019-08-06 ResMed Pty Ltd Method and apparatus for treatment of respiratory disorders
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
IT201900002913A1 (it) 2019-03-01 2020-09-01 Nicola Pescosolido Composto utile per il trattamento del glaucoma
EP4366730A4 (en) 2021-07-05 2025-06-04 Celesta Company LLC Composition for promoting sleep in rest mode and method for its preparation and use
US11833182B2 (en) 2021-08-10 2023-12-05 Shaklee Corporation Sleep product

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5557563A (en) * 1978-10-21 1980-04-28 Hoechst Ag Melatonine nasal application composition
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
JPH0474135A (ja) * 1990-07-13 1992-03-09 Kanegafuchi Chem Ind Co Ltd 点眼組成物
IT1243193B (it) * 1990-08-10 1994-05-24 Medea Res Srl Composizioni farmaceutiche orali a base di melatonina
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
AU660336B2 (en) * 1991-10-18 1995-06-22 Alza Corporation Device for the transdermal administration of melatonin
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin

Also Published As

Publication number Publication date
EP0663825A1 (en) 1995-07-26
WO1994007487A1 (en) 1994-04-14
DE69320485T2 (de) 1999-04-01
US5641801A (en) 1997-06-24
US5449683A (en) 1995-09-12
JPH08502259A (ja) 1996-03-12
DK0663825T3 (da) 1999-05-25
JP3133760B2 (ja) 2001-02-13
CA2146151C (en) 1997-09-02
EP0663825B1 (en) 1998-08-19
ATE169816T1 (de) 1998-09-15
DE69320485D1 (de) 1998-09-24

Similar Documents

Publication Publication Date Title
ES2123064T3 (es) Uso de melatonina en pequeñas dosis orales como somnifero.
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
FI941761A7 (fi) Väline melatoniinin antamiseksi ihon läpi
SE7802944L (sv) Massagegordel for att beras i omradet for menniskans lendkorsrygg
MX9203554A (es) Un dispositivo osmotico para administrar doxazosin
DK0946151T3 (da) Doseringsform med stigende dosisfrigivelse
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
DK0562041T3 (da) Undermættet transdermal lægemiddeludleveringsanordning, der udviser forøget lægemiddelflux
DE68926859D1 (de) Natürlicher killerzellen-stimulationsfaktor
DK162986D0 (da) Terapeutisk middel i enhedsdosisform
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
ES2197500T3 (es) Uso de cloruro de n,n-bis(fenilcarbamoilmetil)dimetilamonio y sus usos derivados en el tratamiento del dolor cronico.
ES290656Y (es) Dispositivo para recoger y mantener vivos los cultivos del cuerpo del paciente.
BR9403783A (pt) Uso de uma composição cosmética
DK505787A (da) Catecholderivater samt forebyggende og terapeutisk praeparat omfattende samme mod regressive sygdomme i centralnervesystemet
SE9701161D0 (sv) New use I
IT7849754A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in particolare ad animali
ES2124256T3 (es) Arilmorfolina, preparacion y uso.
IT1090154B (it) Dispositivo vibratore per sedie poltrone letti e simili
ES2036526T3 (es) Composiciones de interferon.
FR2466251B1 (fr) Vaccin animal anticolibacillaire, obtention et application
SE7700626L (sv) Patientstol for ltandbehandling
IT1091427B (it) Sistema per il controllo dell alimentazione dell araia in pressione e dell acqua ai manipoli ad uso dentistico
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
ES2103811T3 (es) Terapia antiviral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 663825

Country of ref document: ES